The usage of GLP-1 receptor agonists has grown worldwide. This class includes several different injectable medications, as well as an orally delivered drug. Many patients would prefer to avoid injections if possible, and the low absorption of the oral tablets in the stomach is documented as less than 1% per the labeling for RYBELSUS®.
For these reasons, prescribers and patients may prefer a compounded formulation of Semaglutide for sublingual administration, as described here.
Please note that not all sublingual compounds are created the same. In situations where the drug has a high molecular weight, such as Semaglutide, a base with the qualities of SubMagna™ HMW is desired. Please go to www.submagna.com to read additional information about SubMagna™ HMW.
Pursuant to a prescription from a healthcare provider, a compounded sublingual formulation is simple to prepare and has three ingredients: (1) Semaglutide – from RYBELSUS® tablets, (2) SubMagna™ HMW and (3) desired flavoring – often a spearmint/peppermint blend.
The links below house a great deal of information related to Semaglutide and GLP-1 receptor agonist medications in general.